Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Ustekinumab, Treatment for Plaque Psoriasis by Centocor and Janssen-Cilag

Discovered and developed by Centocor, ustekinumab (CNTO 1275) is an investigational MAb with a novel dual mechanism of action. Its initial indication is for the treatment of moderate to severe plaque psoriasis.

Go Top